The validity of this working model is supported by evidence obtained in DS fibroblasts and the Ts65Dn model which show an extended G1 duration that can be reversed by DYRK1A inhibition or knockdown (Chen et al., 2013). The gene discussed is DYRK1A; the disease is Dravet syndrome.